Improved t cell compositions and methods
AssigneeAllogene Therapeutics, Inc.
InventorsJavier Fernando CHAPARRO RIGGERS, Thomas John VAN BLARCOM, Bijan Andre BOLDAJPOUR
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions and methods that downregulate major histocompatibility class I molecule cell surface expression, and uses of such compositions and methods for improving the functional activities of isolated T cells (e.g., gene-modified antigen-specific T cells, such as chimeric antigen receptor T (CAR-T) cells). In particular, the present invention provides methods and compositions for bolstering the therapeutic efficacy of CAR-T cells.
Claims45
An isolated T cell comprising
- (i) a viral protein which decreases cell surface expression level of major histocompatibility complex (MHC) Class I relative to cell surface expression level of MHC Class I of an isolated T cell that does not comprise the viral protein, and
- (ii) a chimeric antigen receptor (CAR) comprising an extracellular ligand-binding domain, a transmembrane domain, and an intracellular signaling domain.
A method of generating an isolated T cell, wherein the method comprises modifying a T-cell expressing a CAR to express a viral protein, wherein the CAR comprises an extracellular ligand-binding domain, a transmembrane domain, and an intracellular signaling domain.
A polynucleotide encoding (i) a viral protein which decreases cell surface expression level of a major histocompatibility complex (MHC) Class I molecule relative to cell surface expression level of MHC Class I molecule of an isolated T cell that does not comprise the viral protein and (ii) a chimeric antigen receptor (CAR).
Dependencies are inferred from the claim text.